Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of switching to Elelyso to assess bone involvement in adults with Gaucher disease previously treated with other enzyme replacement therapy
MOH_2017-04-26_000351Phase 4Recruiting
- Sponsor
- ארי זימרן
- Start
- Sep 2016
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of taliglucerase alfa in Gaucher disease (GD), sponsored by ארי זימרן. Started Sep 2016; status: recruiting.
02
Drugs
taliglucerase alfa
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on MOH_2017-04-26_000351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-26_000351.